JG
FPRX

Jefferies Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Jefferies Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18,132
Closed -$683K – 2190
2021
Q1 		$683K Buy
+18,132
New +$452K 0.01% 1026
2019
Q3 		– Sell
-22,016
Closed -$133K – 3189
2019
Q2 		$133K Buy
22,016
+10,766
+96% +$103K ﹤0.01% 2236
2019
Q1 		$151K Sell
11,250
-6,146
-35% -$70.1K ﹤0.01% 2023
2018
Q4 		$162K Buy
17,396
+3,692
+27% +$43.9K ﹤0.01% 1885
2018
Q3 		$191K Buy
+13,704
New +$204K ﹤0.01% 2123
2017
Q2 		– Sell
-5,602
Closed -$203K – 2716
2017
Q1 		$203K Buy
+5,602
New +$247K ﹤0.01% 2020
2016
Q4 		– Sell
-8,200
Closed -$430K – 2592
2016
Q3 		$430K Sell
8,200
-5,900
-42% -$282K ﹤0.01% 1679
2016
Q2 		$583K Buy
+14,100
New +$613K ﹤0.01% 1367

Jefferies Group's FPRX Position: Q2 2021 in Review

Jefferies Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 18,132 shares — an estimated $683K sold.

Jefferies Group first reported a position in FPRX in Q2 2016 and held it in 8 quarters. The position peaked at $683K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Jefferies Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Jefferies Group sold 18,132 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $683K.
  • Jefferies Group first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 8 quarters.
  • Jefferies Group's Five Prime Therapeutics, Inc. position peaked at $683K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.